479
Participants
Start Date
July 31, 2009
Primary Completion Date
February 28, 2011
Study Completion Date
February 28, 2011
catridecacog
Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
catridecacog
Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
placebo
Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
Novo Nordisk Investigational Site, København Ø
Novo Nordisk Investigational Site, Berlin
Novo Nordisk Investigational Site, Allentown
Novo Nordisk Investigational Site, Philadelphia
Novo Nordisk Investigational Site, San Donato Milanese (MI)
Novo Nordisk Investigational Site, Milan
Novo Nordisk Investigational Site, Durham
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Madrid
Novo Nordisk Investigational Site, Bologna
Novo Nordisk Investigational Site, Valencia
Novo Nordisk Investigational Site, Petah Tikva
Novo Nordisk Investigational Site, Ramat Gan
Novo Nordisk Investigational Site, Frankfurt am Main
Novo Nordisk Investigational Site, Ludwigshafen
Novo Nordisk Investigational Site, Houston
Novo Nordisk Investigational Site, München
Novo Nordisk Investigational Site, Atlanta
Novo Nordisk Investigational Site, Portland
Novo Nordisk Investigational Site, Providence
Novo Nordisk Investigational Site, Toronto
Novo Nordisk Investigational Site, Montreal
Novo Nordisk Investigational Site, Ottawa
Novo Nordisk Investigational Site, Québec
Novo Nordisk Investigational Site, Toronto
Novo Nordisk Investigational Site, Numakunai
Novo Nordisk Investigational Site, Osaka
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Lund
Novo Nordisk Investigational Site, Cambridge
Novo Nordisk Investigational Site, Sheffield
Novo Nordisk Investigational Site, Southampton
Lead Sponsor
Novo Nordisk A/S
INDUSTRY